Loading…
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.4B | $269M | $225M | $118M | 115.3% | 20.2% | - |
| 2024 | $2.0B | $187M | $-11M | $26M | 9.0% | 6.8% | - |
| 2023 | $1.9B | $39M | $-135M | $14M | 105.6% | 6.0% | - |
| 2022 | $1.8B | $-525M | $-662M | $-60M | 15857.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1,787.64 | 1,895.21 | 2,024.51 | 2,433.20 |
| Cost Of Revenue | 1,234.42 | 1,299.78 | 1,388.96 | 1,622.72 |
| Gross Profit | 553.23 | 595.43 | 635.54 | 810.48 |
| Operating Expense | 520.06 | 481.76 | 494.26 | 550.21 |
| Operating Income | 33.17 | 113.67 | 141.28 | 260.28 |
| EBITDA | -525.06 | 39.17 | 187.38 | 269.40 |
| EBIT | -563.87 | 9.07 | 156.21 | 241.18 |
| Pretax Income | -663.81 | -139 | 5.07 | 106.95 |
| Tax Provision | -1.78 | -4.47 | 16 | -118.09 |
| Net Income | -662.03 | -134.52 | -10.93 | 225.03 |
| Net Income Common Stockholders | -662.03 | -134.52 | -10.93 | 225.03 |
| Total Expenses | 1,754.48 | 1,781.54 | 1,883.23 | 2,172.92 |
| Interest Expense | 99.94 | 148.07 | 151.14 | 134.23 |
| Interest Income | 0.68 | 0.33 | 0.50 | 2.83 |
| Selling General And Administration | 483.95 | 464.74 | 470.47 | 528.80 |
| Normalized EBITDA | 65.12 | 139.16 | 167.52 | 285.52 |
| Normalized Income | -73.44 | -37.73 | -26.62 | 234.71 |
| Basic EPS | -3.57 | -0.71 | -0.06 | 0 |
| Diluted EPS | -3.57 | -0.71 | -0.06 | 0 |
| Tax Effect Of Unusual Items | -1.58 | -3.20 | 4.17 | -6.45 |
| Tax Rate For Calcs | 0 | 0.03 | 0.21 | 0.40 |
| Total Unusual Items | -590.18 | -99.99 | 19.86 | -16.12 |
| Total Unusual Items Excluding Goodwill | -590.18 | -99.99 | 19.86 | -16.12 |
| Net Income From Continuing Operation Net Minority Interest | -662.03 | -134.52 | -10.93 | 225.03 |
| Reconciled Depreciation | 38.82 | 30.10 | 31.16 | 28.22 |
| Reconciled Cost Of Revenue | 1,216.91 | 1,283.46 | 1,368.58 | 1,605.03 |
| Net Interest Income | -107.04 | -152.92 | -156.10 | -137.25 |
| Net Income From Continuing And Discontinued Operation | -662.03 | -134.52 | -10.93 | 225.03 |
| Rent Expense Supplemental | 12.50 | 12.34 | 12.65 | 13.51 |
| Total Operating Income As Reported | -642.28 | 8.07 | 139.79 | 256.46 |
| Diluted Average Shares | 185.55 | 189.96 | 192.89 | 0 |
| Basic Average Shares | 185.55 | 189.96 | 192.89 | 0 |
| Diluted NI Availto Com Stockholders | -662.03 | -134.52 | -10.93 | 225.03 |
| Net Income Including Noncontrolling Interests | -662.03 | -134.52 | -10.93 | 225.03 |
| Net Income Continuous Operations | -662.03 | -134.52 | -10.93 | 225.03 |
| Other Income Expense | -589.94 | -99.75 | 19.90 | -16.07 |
| Other Non Operating Income Expenses | 0.24 | 0.24 | 0.04 | 0.05 |
| Special Income Charges | -675.45 | -105.60 | -1.49 | -9.68 |
| Other Special Charges | 0 | 0 | 0 | 5.86 |
| Impairment Of Capital Assets | 675.35 | 105.14 | 0 | 0 |
| Restructuring And Mergern Acquisition | 0.10 | 0.47 | 1.49 | 3.81 |
| Gain On Sale Of Security | 85.27 | 5.61 | 21.35 | -6.44 |
| Net Non Operating Interest Income Expense | -107.04 | -152.92 | -156.10 | -137.25 |
| Total Other Finance Cost | 7.78 | 5.18 | 5.46 | 5.85 |
| Interest Expense Non Operating | 99.94 | 148.07 | 151.14 | 134.23 |
| Interest Income Non Operating | 0.68 | 0.33 | 0.50 | 2.83 |
| Other Operating Expenses | 14.80 | 3.24 | 13.02 | 10.87 |
| Depreciation Amortization Depletion Income Statement | 21.31 | 13.78 | 10.78 | 10.54 |
| Depreciation And Amortization In Income Statement | 21.31 | 13.78 | 10.78 | 10.54 |
| General And Administrative Expense | 483.95 | 464.74 | 470.47 | 528.80 |
| Other Gand A | 393.15 | 382.81 | 376.28 | 420.26 |
| Rent And Landing Fees | 12.50 | 12.34 | 12.65 | 13.51 |
| Salaries And Wages | 78.30 | 69.59 | 81.54 | 95.03 |
| Operating Revenue | 1,787.64 | 1,895.21 | 2,024.51 | 2,433.20 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aveanna Healthcare Holdings Inc.this co. | AVAH | $1.4B | 6.24 | 7.08 | 115.3% | 9.48 |
| Precigen, Inc. | PGEN | $1.5B | - | 69.83 | -1198.6% | -14.11 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | - | 3.57 | -36.9% | -6.82 |
| Alphatec Holdings, Inc. | ATEC | $1.4B | - | 112.05 | -1153.7% | 95.59 |
| Bicara Therapeutics Inc. | BCAX |
| $1.4B |
| - |
| 2.89 |
| -34.4% |
| -6.30 |
| ArriVent BioPharma, Inc. | AVBP | $1.4B | - | 4.15 | -54.1% | - |
| AtriCure, Inc. | ATRC | $1.4B | - | 2.77 | 0.0% | 114.65 |
| Biohaven Ltd. | BHVN | $1.4B | - | 23.47 | -1418.8% | -1.93 |
| NovoCure Limited | NVCR | $1.4B | - | 3.94 | -40.0% | -8.57 |
| Peer Median | - | - | 4.05 | -47.1% | -6.30 | |